Valganciclovir

Renal impairment

See relevant local guideline:

Virus Management in solid organ transplant recipients and islet cell transplant recipients

OR 

Management of CMV reactivation and infection in allogeneic BMT recipients

Hepatic impairment

• No information available for use in hepatic impairment. SPC states "The safety and efficacy of valganciclovir have not been studied in patients with hepatic impairment. Hepatic impairment should not affect the pharmacokinetics of ganciclovir since it is excreted renally and, therefore, no specific dose recommendation is made."

1. Generics [UK] Ltd t/a Mylan. Valganciclovir 450 mg Film-coated Tablets summary of product characteristics. Electronic medicines compendium. Last revision of the text 08/2022. Accessed via www.medicines.org.uk Accessed 16/9/26
2. British National Formulary. Valganciclovir. Accessed via BNF accessed via www.medicinescomplete.com  Accessed 16/9/26.
3. The Renal Drug Database. Valganciclovir. Last updated 30/10/24. Accessed via https://renaldrugdatabase.com Accessed 16/9/26.
4. Jeffery K, Mason P, Devaney A. Virus Management in solid organ transplant recipients and islet cell transplant recipients. OUH clinical guideline. Accessed via: https://ouhnhsuk.sharepoint.com/sites/RenalTransplantUnit/Shared%20Documents/Transplant/Clinical%20Guidelines/Virus%20management%20module.pdf Accessed 16/9/26.
5. Sanford Guide [online]. Valganciclovir. Last updated 8/9/26. Accessed 16/9/26